Background: In the past decade, there has been a global emergence of Carbapenem-resistant Gram-negative bacilli, especially Enterobacterales. Carbapenem resistance is attributed to the ability of the bacteria to produce Carbapenemases. The aim of the study is to detect Carbapenem-resistant Enterobacterales in different clinical isolates and study Carbapenemase production by phenotypic method in Carbapenem-resistant Enterobacterales. Methods: A total of 379 Enterobacterales were isolated from different clinical samples from patients attending OPDs and admitted in wards and ICUs. They were tested for Carbapenem resistance by Kirby-Bauer Disk-Diffusion Method, and then tested for Carbapenemase production by EDTA Disk Synergy Test and Modified Carbapenem Inactivation Method. Results: This study was conducted from February 2021 to August 2022. Out of 379 Enterobacterales, 70 (18.47%) were Carbapenem-resistant Enterobacterales (CRE). Maximum Carbapenem resistance was shown by Klebsiella pneumoniae at 23.53%. The maximum Carbapenem resistance was seen in age-group of 16 to 45 years and the most number of CRE isolates were from Intensive Care Units. Phenotypic test results indicated that 54.28% (38/70) isolates were positive for Carbapenemase production by either of the phenotypic methods. Conclusion: Carbapenem resistance in our study was 18.47% (70/379). This study highlights the use of phenotypic methods to detect Carbapenemase production in Carbapenem-resistant Enterobacterales, which is responsible for multi-drug resistance. This information is relevant for surveillance, to implement infection prevention and control practices and antibiotic policies